Please ensure Javascript is enabled for purposes of website accessibility

Why Nurix Therapeutics Stock Soared More Than 21% Wednesday

By Jim Halley – Oct 27, 2021 at 5:17PM

Key Points

  • Nurix Therapeutics jumped up nearly $5 a share on Wednesday.
  • The company just released data from a phase 1a trial for its lead BTK inhibitor therapy.
  • The company does not yet have any marketed drugs.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage biopharmaceutical company posted positive news regarding its lead therapy -- a BTK inhibitor that could fight certain blood-based cancers.

What happened

Nurix Therapeutics (NRIX 7.85%) stock soared more than 21% on Wednesday. The stock, which closed at $28.96 on Tuesday, opened at $31.25 and rose as high as $36.24 in mid-day training. The stock's 52-week high is $52.38, and its low is $21.53.

Laboratory worker looks at a blue chemical solution in a beaker.


So what

The biopharmaceutical company released initial phase 1a data regarding NX-2127, its therapy for patients with relapsed or refractory B-cell cancers. According to Nurix, the drug was able to significantly reduce Bruton's tyrosine kinase (BTK) in all of the patients in the trial. BTK is an enzyme that is a key part of the B-cell receptor-signaling pathways. By blocking the enzyme, certain B-cell leukemias and lymphomas will not be able to grow and survive.

BTK inhibitors have been shown to be effective against chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and other B-cell malignancies. Final approval  for NX-2127 will depend on its safety and continued efficacy as the trials continue.

Now what

This is certainly a big deal for Nurix, which has other drugs in its pipeline, including immune-oncology drugs and adoptive cell therapies. However, none of these are past the preclinical stage. The company's only revenue in the third quarter was from collaboration revenue, which was not enough to put the company in the black. In the third quarter, it reported revenue of $10.3 million, while the company posted a net loss of $28.8 million. With cash reserves of $465.4 million, the company is in good shape to last three years of cash burn until NX-2127 or any of its other pipeline drugs can come to market.

Nurix is facing potential competition from other pharmaceutical companies. There are three BTK inhibitors on the market, all of which are known to have significant side effects: ibrutinib, acalabrutinib and zanubrutinib.  But according to a July article in the International Journal of Molecular Sciences, there are more than two dozen other BTK inhibitors that are being tested.

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.